Navigation Links
Urgent® PC Clinical Studies Results Scheduled for Presentation at International Continence Society

MINNETONKA, Minn., Aug. 15, 2011 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of two clinical studies using Uroplasty's Urgent® PC Neuromodulation System are scheduled to be presented at the International Continence Society meeting, August 29-September 2, 2011 in Glasgow, Scotland.  

"These data from on-going clinical studies continue to demonstrate the long-term efficacy of percutaneous tibial nerve stimulation (PTNS) delivered via Urgent PC in the treatment of overactive bladder syndrome," said David Kaysen, President and CEO of Uroplasty.  "The studies build on a growing body of evidence that validates the treatment protocol, usefulness with both young and elderly patients, and the durability of the improvements with continued PTNS therapy."  

ICS Presentations

  • SUmiT Trial Outcomes: Clinical Insights into Percutaneous Tibial Nerve Stimulation, presented by Dr. Peter Sand, NorthShore University Health, Chicago, IL
  • Demonstrated that results are consistent for patients regardless of age
  • Demonstrated that improvement occurs throughout the series of 12 initial treatments, with more improvement occurring during treatments 7 through 12
  • Treatment Interval Frequency of Percutaneous Tibial Nerve Stimulation: 18-Month Results from the STEP Study, presented by Dr. Kenneth Peters, William Beaumont Hospital, Royal Oak, MI
  • Responders to the initial series of 12 treatments treated with regular PTNS therapy, on an average of once per month, sustained their improvements in voiding symptoms and Quality of Life measures throughout 18 months of therapy  

  • About Uroplasty Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions.  Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence.  We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.  For more information on the company and its products, please visit Uroplasty, Inc. at

    Safe HarborThis press release contains forward-looking statements that reflect our best estimates regarding future events that could affect our financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report and on Form 10-K filed with the SEC.  We cannot be certain that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.Company Contact:Investor Relations Contacts:Media Contact:Uroplasty, Inc.

    EVC Group, Inc.

    EVC Group, Inc.David Kaysen, CEO

    Doug Sherk/Jenifer Kirtland

    Chris Gale/ Steve DiMattia(952) 426-6140

    (415) 568-9349


    SOURCE Uroplasty, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplastys Urgent® PC Neuromodulation System
    2. Additional Regional Medicare Carrier Initiates Coverage for Posterior Tibial Nerve Stimulation (PTNS) Delivered via Uroplastys Urgent® PC Neuromodulation System
    3. Uroplasty Announces Expanded Insurance Coverage of Posterior Tibial Nerve Stimulation (PTNS) Delivered Using the Urgent® PC Neuromodulation System
    4. Two Additional Private Payers Provide Coverage for Posterior Tibial Nerve Stimulation Delivered Using the Uroplasty Urgent® PC Neuromodulation System
    5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
    10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
    11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
    Post Your Comments:
    (Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
    (Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
    (Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Italian therapeutic drug monitoring ...
    Breaking Medicine Technology:
    (Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Association meeting in Washington D.C. revolved around the fact that proper dental care, both ... talk stressed the link between periodontal disease (more commonly referred to as gum disease) ...
    (Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
    (Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
    (Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, I ... Hillside, N.J. "Many people catch diseases simply from sitting on such dirty toilet ... protected from germs." , He developed the patent-pending QUDRATECS to eliminate the need ...
    (Date:11/27/2015)... ... , ... The print component of “Supporting Our Caregivers” is ... York, Minneapolis, South Florida, with a circulation of approximately 250,000 copies and an ... social media strategy and across a network of top news sites and partner ...
    Breaking Medicine News(10 mins):